Biotricity announces inclusion as a supplier to a prominent medical system that services 21 states

REDWOOD CITY, Calif., Sep 26, 2024 (ACCESSWIRE) - Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease. Yet nearly half of U.S. counties do not have a practicing cardiologist, leaving patients in these areas with a roundtrip of over 85 miles to see a heart specialist versus 16 miles for those in a county with at least 1 cardiologist.

"At Biotricity, we're dedicated to closing the wide gap in cardiovascular care across the nation," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "Our inclusion as a supplier to this prominent medical system represents a significant step forward in ensuring that our innovative solutions are accessible to providers and patients. We're committed to transforming the landscape of healthcare delivery to improve patient outcomes, especially in underserved communities. As rollouts like this occur, Biotricity's path to profitability will accelerate."
Biotricity offers the only 3-lead compact connected cardiac monitoring device in the world- Biocore. Biocore is small in size and large in data, with the best diagnostic yield in the industry to minimize patient risk and optimize outcomes. The company's solutions are trusted by over 2,500 cardiologists in over 500 locations. This partnership not only expands Biotricity's market reach but also underscores its commitment to addressing critical gaps in cardiovascular care across the nation. For more information about Biotricity and its innovative healthcare solutions, please visit Biotricity.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
[email protected]